➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
McKesson
Dow
Merck
Harvard Business School

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYCAMTIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Hycamtin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003415 ↗ Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome Completed University of Arizona Phase 1/Phase 2 1998-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus topotecan in treating patients with myelodysplastic syndrome.
NCT00003733 ↗ Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer Unknown status SmithKline Beecham Phase 2 1997-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of sequential chemotherapy in treating patients with residual disease following surgery for stage IIB, stage III, or stage IV ovarian cancer.
NCT00014443 ↗ Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma Unknown status Rush University Medical Center Phase 1 2000-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of combining topotecan and thalidomide in treating patients who have recurrent or refractory malignant glioma.
NCT00057720 ↗ TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer Completed Telik Phase 3 2003-06-01 The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.
NCT00065182 ↗ Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer Completed GlaxoSmithKline Phase 2 2003-08-01 The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one previous chemotherapy excluding TAXOTERE or HYCAMTIN.
NCT00087126 ↗ Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer Completed National Cancer Institute (NCI) Phase 2 2005-02-01 RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well topotecan works in treating women with persistent or recurrent cervical cancer.
NCT00087126 ↗ Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer Completed Gynecologic Oncology Group Phase 2 2005-02-01 RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well topotecan works in treating women with persistent or recurrent cervical cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hycamtin

Condition Name

Condition Name for Hycamtin
Intervention Trials
Ovarian Cancer 7
Lung Cancer, Small Cell 4
Solid Tumors 3
Neuroblastoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hycamtin
Intervention Trials
Small Cell Lung Carcinoma 9
Lung Neoplasms 9
Ovarian Neoplasms 8
Neoplasms 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hycamtin

Trials by Country

Trials by Country for Hycamtin
Location Trials
United States 169
Canada 21
United Kingdom 8
Brazil 6
Czech Republic 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hycamtin
Location Trials
California 8
Ohio 8
Illinois 8
New York 7
Florida 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hycamtin

Clinical Trial Phase

Clinical Trial Phase for Hycamtin
Clinical Trial Phase Trials
Phase 3 5
Phase 2 17
Phase 1/Phase 2 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hycamtin
Clinical Trial Phase Trials
Completed 19
Not yet recruiting 8
Recruiting 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hycamtin

Sponsor Name

Sponsor Name for Hycamtin
Sponsor Trials
National Cancer Institute (NCI) 9
GlaxoSmithKline 8
M.D. Anderson Cancer Center 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hycamtin
Sponsor Trials
Other 24
Industry 16
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Medtronic
Colorcon
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.